I would echo Pascal’s point. Getting pharmacometric work into large clinical conferences is not straightforward. It can be done (see link) http://erj.ersjournals.com/content/46/suppl_59/PA5091.abstract but note where I was in the author list as the sole modeller. It helps to work closely with the clinicians on the messaging. That said, it was fun at the meeting, explaining the data and model curves to clinicians with them asking how such knowledge could impact their patients. An eye-opener. Keep trying Naoto!
All the best, Phil Philip J Lowe PhD Executive Director Pharmacometrics Scientist Novartis Pharma AG, WSJ-027.6.25 or WSJ-386.12.48.46 4056 Basel, Switzerland Phone: +41 61 324 4676 [email protected]<mailto:[email protected]> From: [email protected] [mailto:[email protected]] On Behalf Of Pascal Girard Sent: 06 April 2016 10:39 To: Naoto Hayashi; [email protected] Cc: nmusers Subject: RE: [NMusers] ASCO and pharmacometrics Dear Naoto, In the past, Rene Bruno got one poster accepted with discussion at ASCO. He is our ”champion” ! I got one accepted on model for Exp-Tumor Size – OS at European Cancer Congress 2013 . But I can tell you that a medical writer rewrote it entirely and it took 1 month to get it reviewed and corrected by clinicians challenging every comma and p-value. To give you an idea of the respective size of the meetings: ACOP N=500, PAGE N>600, ECC N> 10,000, ASCO N>20,000. So the advice I would give, is just improve the quality and readability of our abstract and it will make it. By readability, I mean show it to an oncologist clinician. If he does not understand, rewrite it with the help of a medical writer … With best regards / Mit freundlichen Grüßen / Cordialement Pascal
